The crude incidence of lung cancer in the EU is 52.5/100 000/ year, the mortality 48.7/100 000/year. Among men the rates are 82.5 and 77.0/100 000/year, among women 23.9 and 22.3/100 000/year, respectively. NSCLC accounts for 80% of all cases. About 90% of lung cancer mortality among men (and 80% among women) is attributable to smoking. diagnosis Pathological diagnosis should be made according to the WHO classification from a biopsy or fine needle aspiration. EGFR mutation analysis may be performed if feasible and the use of EGFR tyrosine-kinase inhibitors (TKIs) is being considered.
diagnosis
Pathological diagnosis should be made according to the WHO classification from a biopsy or fine needle aspiration. EGFR mutation analysis may be performed if feasible and the use of EGFR tyrosine-kinase inhibitors (TKIs) is being considered.
staging and risk assessment
Complete history and physical examination, CT scan of the chest and upper abdomen. MRI of the brain if abnormal neurologic history or examination (to be substituted by CT scan if MRI not available). Bone scintigraphy in the presence of bone pain, elevated serum calcium level or elevated alkaline phosphatase level. 
patients with potentially curative treatment

response evaluation of stage IV disease
Response evaluation is mandatory after two or three cycles of chemotherapy by repetition of the initial radiographic tests showing tumor lesions. Clinical benefit can be used in certain groups of patients.
follow-up
The optimal approach to post-treatment management of patients with thoracic malignancies, including the role of radiologic evaluation, is controversial. For patients with potentially curative re-treatment, a history and physical examination should be performed every 3-6 months during the first 2 years, and every 6-12 months thereafter and radiologic evaluations should be considered at these time points. 
